Trending

AAPL

AMZN

$127.38 $1.39 1.11%

TSLA

$250.05 $3.67 1.49%

GOOG

$131.83 $1.30 0.98%

Market Movers, Stocks

24/7 Market News – (NASDAQ: DBTX) shares are poised to gain as they report top line data from Phase 1 trial.

by 24/7 MarketNews Admin

Jun 28, 2022 at 6:56 AM

Shares are at bid at $2.55 and do not trade much for premarket. The stocks highest volume day was in 2021 with only 4 million shares traded. The stock has drifted down over the past year on light volume.

Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy

https://www.globenewswire.com/news-release/2022/06/28/2470202/0/en/Decibel-Therapeutics-Reports-Positive-Data-from-Interim-Analysis-of-Ongoing-Phase-1b-Clinical-Trial-of-DB-020-in-Patients-Receiving-Cisplatin-Chemotherapy.html

RelatedNews

24/7 Market News Snapshot 29 Sept 2023

SeaStar Medical Receives FDA Breakthrough Device Designation for its Selective Cytopheretic Device for Cardiorenal Syndrome

Femasys Momentum continues after Two Announcements the Week

24/7 Market News Snapshot 28 Sept 2023

FDA Grants Baudax Bio Orphan Drug Designation for TI-168 for the Treatment of Hemophilia A with Inhibitors

Page 1 of 2

12 Next

Want more news like this? Check out our homepage!

Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

24/7 Market News Snapshot 29 Sept 2023

September 29, 2023

SeaStar Medical Receives FDA Breakthrough Device Designation for its Selective Cytopheretic Device for Cardiorenal Syndrome

September 29, 2023

Femasys Momentum continues after Two Announcements the Week

September 29, 2023

24/7 Market News Snapshot 28 Sept 2023

September 28, 2023

FDA Grants Baudax Bio Orphan Drug Designation for TI-168 for the Treatment of Hemophilia A with Inhibitors

September 28, 2023

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

24/7 MarketNews is a leading market news platform for public companies. As a pioneer in digital media, we are dedicated to the swift distribution of financial market news and information. We take great pride in creating innovative public relations campaigns that help our clients reach their target audience.

24/7 Market News – (NASDAQ: DBTX) shares are poised to gain as they report top line data from Phase 1 trial.

Shares are at bid at $2.55 and do not trade much for premarket. The stocks highest volume day was in 2021 with only 4 million shares traded. The stock has drifted down over the past year on light volume.

Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy

RelatedNews

24/7 Market News Snapshot 29 Sept 2023

SeaStar Medical Receives FDA Breakthrough Device Designation for its Selective Cytopheretic Device for Cardiorenal Syndrome

Femasys Momentum continues after Two Announcements the Week

24/7 Market News Snapshot 28 Sept 2023

FDA Grants Baudax Bio Orphan Drug Designation for TI-168 for the Treatment of Hemophilia A with Inhibitors

Want more news like this? Check out our homepage!

Recent News

24/7 Market News Snapshot 29 Sept 2023

SeaStar Medical Receives FDA Breakthrough Device Designation for its Selective Cytopheretic Device for Cardiorenal Syndrome

Femasys Momentum continues after Two Announcements the Week

24/7 Market News Snapshot 28 Sept 2023

FDA Grants Baudax Bio Orphan Drug Designation for TI-168 for the Treatment of Hemophilia A with Inhibitors

Follow Us

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Search by keyword

Add New Playlist